Nuclear transport modulators and uses thereof

A compound of formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is an optionally substituted triazolyl ring;
• Ring B is represented by the following structural formula:
• X is O;
• Y is a covalent bond;
• R1 and R2 are taken together with their intervening atoms to form a heterocyclic ring represented by the following structural formula:
• each of m, and p is independently an integer selected from 0, 1, 2, 3 and 4;
• q is 0;
• each of R4, and R5 is independently halogen, —NO2, —CN, —N3, -L-R6, or an optionally substituted group selected from C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aryl ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
• two R4 groups on Ring A are taken together with their intervening atoms to form a fused 4-8 membered saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• or:
• two R5 groups on the ring formed by R1 and R2 are taken together with their intervening atoms to form a fused 4-8 membered saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• L is a covalent bond or an optionally substituted bivalent C1-6 hydrocarbon group, wherein one or two methylene units of L is optionally and independently replaced by -Cy-, —O—, —S—, —N(R6)—, —C(O)—, —C(S)—, —C(O)N(R6)—, —N(R6)C(O)N(R6)—, —N(R6)C(O)—, —N(R6)C(O)O—, —OC(O)N(R6)—, —S(O)—, —S(O)2—, —S(O)2N(R6)—, —N(R6)S(O)2—, —OC(O)— or —C(O)O—;
• -Cy- is an optionally substituted bivalent ring selected from a 3-7 membered saturated or partially unsaturated cycloalkylenylene ring, a 4-7-membered saturated or partially unsaturated heterocycloalkylene ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, phenylene, a 5-6 membered monocyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic arylene, and an 8-10 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• and
• each R6 is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, an 8-10 membered bicyclic saturated, partially unsaturated or aryl carbocyclic ring, a 4-7-membered saturated or partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
• or:
• two R6 on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or aromatic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.